Allegations of sham pharma patent litigation are growing, but claimants have a mountain to climb
Akorn Inc’s failure to make its case against Allergan and Duke is a reminder that challenging life sciences patentees remains a tough task
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.